{"qas": [{"question": "What vaccine are researchers trying to improve on?", "id": "5727ec2c3acd2414000deff7", "answers": [{"text": "BCG", "answer_start": 4}], "is_impossible": false}, {"question": "What phase of clinical trials have some new vaccine options reached?", "id": "5727ec2c3acd2414000deff8", "answers": [{"text": "I and II", "answer_start": 141}], "is_impossible": false}, {"question": "What does one option propose adding to the existing BCG vaccine? ", "id": "5727ec2c3acd2414000deff9", "answers": [{"text": "subunit vaccine", "answer_start": 291}], "is_impossible": false}, {"question": "What's the name of the subunit vaccine being studied in South Africa?", "id": "5727ec2c3acd2414000deffa", "answers": [{"text": "MVA85A", "answer_start": 394}], "is_impossible": false}, {"question": "What genetically modified virus was used to develop MVA85A?", "id": "5727ec2c3acd2414000deffb", "answers": [{"text": "vaccinia", "answer_start": 507}], "is_impossible": false}, {"plausible_answers": [{"text": "BCG", "answer_start": 4}], "question": "What candidate is in phase I and II?", "id": "5a873f7f1d3cee001a6a113a", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "BCG", "answer_start": 310}], "question": "What is added to a subunit vaccine?", "id": "5a873f7f1d3cee001a6a113b", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "South Africa", "answer_start": 458}], "question": "Where is BCG in trials?", "id": "5a873f7f1d3cee001a6a113c", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "Two", "answer_start": 167}], "question": "How many main limitations does the BCG vaccine have?", "id": "5a873f7f1d3cee001a6a113d", "answers": [], "is_impossible": true}, {"plausible_answers": [{"text": "vaccinia", "answer_start": 507}], "question": "What virus is BCG based on?", "id": "5a873f7f1d3cee001a6a113e", "answers": [], "is_impossible": true}], "context": "The <a0_0><b5_0>BCG<b5_0/><a0_0/> vaccine has limitations, and research to develop new TB vaccines is ongoing. A number of potential candidates are currently in phase <a1_0>I and II<a1_0/> clinical trials. <b8_0>Two<b8_0/> main approaches are being used to attempt to improve the efficacy of available vaccines. One approach involves adding a <a2_0>subunit vaccine<a2_0/> to <b6_0>BCG<b6_0/>, while the other strategy is attempting to create new and better live vaccines. <a3_0>MVA85A<a3_0/>, an example of a subunit vaccine, currently in trials in <b7_0>South Africa<b7_0/>, is based on a genetically modified <a4_0><b9_0>vaccinia<b9_0/><a4_0/> virus. Vaccines are hoped to play a significant role in treatment of both latent and active disease."}